MECHANISM OF ACTION
Enzalutamide acts as a pure androgen receptor antagonist that competitively inhibits the binding of androgen to androgen receptors. Enzalutamide also inhibits the nuclear translocation of the androgen receptor and DNA binding, resulting in decreased coactivator recruitment. This has been shown in vitro to reduce cell proliferation and increase apoptosis of prostate cancer cells.
PHARMACOKINETICS
Enzalutamide's kinetics can be described by a linear 2-compartment model with first-order absorption. Following the administration of a single oral dose, the volume of distribution (Vd) is approximately 110 L. Absorption is unaffected by meals; the area under the time-concentration curve (AUC) of enzalutamide and N-desmethyl enzalutamide both remain similar. Both enzalutamide and N-desmethyl enzalutamide are highly protein bound, approximately 97% to 98% and 95%, respectively. After oral administration, enzalutamide is rapidly absorbed, with a mean time to reach peak plasma concentration (C max ) of about 1 hour (range, 0.5 to 4 hours). With daily dosing, steady state is usually achieved by day 28. At steady state, enzalutamide plasma concentrations have an average peak-to-trough ratio of 1.25. At steady state, the average peak plasma concentrations (C max ) for enzalutamide and its active metabolite, N-desmethyl enzalutamide, are 16.6 mcg/mL and 12.7 mcg/mL, respectively. The average minimum plasma concentrations (C min ) are 11.4 mcg/mL and 13.0 mcg/mL, respectively. Enzalutamide undergoes hepatic metabolism, primarily by CYP2C8 and CYP3A4. N-desmethyl enzalutamide (active metabolite) and a carboxylic acid metabolite (inactive metabolite) are the major metabolites. The estimated half-life of enzalutamide after a single dose is about 6 to 7 days (range, 3-13 days), with a mean terminal half-life for N-desmethyl enzalutamide of 8 to 9 days. Approximately 71% of the drug is excreted in the urine and 14% in the feces.
Selected therapeutic regimens of enzalutamide appear in Table 1 . 
PREPARATION

Name: Ruxolitinib
Synonyms: INCB018424, Jakafi
MECHANISM OF ACTION
Ruxolitinib is a strong, selective ATP-competitive inhibitor of the Janus associated kinases (JAK) 1 and 2 enzymes. These enzymes are responsible for mediating cytokine and growth factor signaling, which play a significant role in hematopoiesis and immune function. Signal transducers and activators of transcription (STATs) are recruited through JAK signaling. The binding of STATs to cytokine receptors causes activation and eventual migration of STATs to the nucleus, which allows for modification or mutation of gene expression.
PHARMACOKINETICS
Ruxolitinib has good oral bioavailability (greater than 95%) and is rapidly absorbed. It usually reaches peak concentrations (C max ) within 2 hours of administration. The C max and total exposure (AUC) of ruxolitinib increase linearly with the dose. Steady state is usually reached by day 2, regardless of dose. Ingestion of ruxolitinib is not greatly affected by food. C max decreases approximately 24% when taken with a high-fat meal versus fasting; there is little affect on the AUC. The volume of distribution (V d ) is estimated to range from 53 to 97 L. Ruxolitinib is 97% protein bound, primarily to albumin. Ruxolitinib is largely The individual dose is half the daily dose (eg, 20 mg/day 5 10 mg twice a day). Care should be taken ensure the intended daily dose is not taken twice a day.
